Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10,783 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical Outcomes of Patients with High-risk Metastatic Hormone-naïve Prostate Cancer: A 3-year Interim Analysis of the Observational J-ROCK Study.
Miyake H, Matsumoto R, Fujimoto K, Mizokami A, Uemura H, Kamoto T, Kawakami S, Nakamura K, Maekawa S, Shibayama K, Watanabe A, Ito M, Tajima Y, Matsuyama H, Uemura H. Miyake H, et al. Among authors: ito m. Eur Urol Oncol. 2024 Jun;7(3):625-632. doi: 10.1016/j.euo.2023.12.013. Epub 2024 Jan 30. Eur Urol Oncol. 2024. PMID: 38296736 Free article.
Treatment strategies and outcomes in a long-term registry study of patients with high-risk metastatic hormone-naïve prostate cancer in Japan: An interim analysis of the J-ROCK study.
Uemura H, Matsumoto R, Mizokami A, Miyake H, Uemura H, Matsuyama H, Nakamura K, Saito K, Kawakita M, Takeshita H, Koroki Y, Ono S, Murota M, Ito M, Kamoto T, Fujimoto K. Uemura H, et al. Among authors: ito m. Int J Urol. 2022 Sep;29(9):1061-1070. doi: 10.1111/iju.14993. Epub 2022 Aug 26. Int J Urol. 2022. PMID: 36018236 Free PMC article.
Safety and efficacy of apalutamide in Japanese patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo-controlled, phase III TITAN study.
Uemura H, Arai G, Uemura H, Suzuki H, Aoyama J, Hatayama T, Ito M, Lefresne F, McCarthy S, Mundle S, He J, Chi KN. Uemura H, et al. Among authors: ito m. Int J Urol. 2022 Jun;29(6):533-540. doi: 10.1111/iju.14843. Epub 2022 Mar 15. Int J Urol. 2022. PMID: 35293030 Free PMC article. Clinical Trial.
Highly Permeable and Regenerative Microhoneycomb Filters.
Liu M, Pan ZZ, Ohwada M, Tang R, Matsui H, Tada M, Ito M, Ikura A, Nishihara H. Liu M, et al. Among authors: ito m. ACS Appl Mater Interfaces. 2024 May 23. doi: 10.1021/acsami.4c02697. Online ahead of print. ACS Appl Mater Interfaces. 2024. PMID: 38781454
Meta-analysis of shotgun sequencing of gut microbiota in Parkinson's disease.
Nishiwaki H, Ueyama J, Ito M, Hamaguchi T, Takimoto K, Maeda T, Kashihara K, Tsuboi Y, Mori H, Kurokawa K, Katsuno M, Hirayama M, Ohno K. Nishiwaki H, et al. Among authors: ito m. NPJ Parkinsons Dis. 2024 May 21;10(1):106. doi: 10.1038/s41531-024-00724-z. NPJ Parkinsons Dis. 2024. PMID: 38773112 Free PMC article.
Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks).
Takano T, Masuda N, Ito M, Inoue K, Tanabe Y, Kawaguchi K, Yasojima H, Bando H, Nakamura R, Yamanaka T, Ishida K, Aruga T, Yanagita Y, Tokunaga E, Aogi K, Ohno S, Kasai H, Kataoka TR, Morita S, Toi M. Takano T, et al. Among authors: ito m. Breast Cancer Res Treat. 2024 May 20. doi: 10.1007/s10549-024-07333-7. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 38767786
10,783 results
You have reached the last available page of results. Please see the User Guide for more information.